AUPH - Aurinia announces resignations of medical chief and senior research executive

• Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH ) lost ~4% pre-market Friday after the company announced that its Chief Medical Officer, Neil Solomons, and Executive Vice President, Research, Robert Huizinga, will resign from their positions effective Oct. 31.
• The disclosure made via a regulatory filing includes the terms of the resignations, as agreed between the parties on Oct. 17.
• Aurinia ( AUPH ) shares surged ahead of the announcement on Thursday, exactly a year after Bloomberg reported that pharma giant Bristol Myers ( BMY ) approached to make a buyout offer for the company.
• Aurinia ( AUPH ), the developer of lupus nephritis therapy, Lupkynis, has lost more than 60% of its value over the past 12 months, as indicated in this graph.

For further details see: